Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Baxter
AstraZeneca
Boehringer Ingelheim
Colorcon

Last Updated: June 27, 2022

VOCABRIA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Vocabria patents expire, and when can generic versions of Vocabria launch?

Vocabria is a drug marketed by Viiv Hlthcare and is included in one NDA. There are two patents protecting this drug.

This drug has one hundred and nineteen patent family members in thirty-one countries.

The generic ingredient in VOCABRIA is cabotegravir sodium. One supplier is listed for this compound. Additional details are available on the cabotegravir sodium profile page.

DrugPatentWatch® Generic Entry Outlook for Vocabria

Vocabria will be eligible for patent challenges on January 21, 2025. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be April 28, 2026. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try it Free

Summary for VOCABRIA
International Patents:119
US Patents:2
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 55
Patent Applications: 374
What excipients (inactive ingredients) are in VOCABRIA?VOCABRIA excipients list
DailyMed Link:VOCABRIA at DailyMed
Drug patent expirations by year for VOCABRIA
DrugPatentWatch® Estimated Generic Entry Opportunity Date for VOCABRIA
Generic Entry Date for VOCABRIA*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for VOCABRIA

VOCABRIA is protected by four US patents and two FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of VOCABRIA is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting VOCABRIA

N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a- -hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

(3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5- ,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HIV-1 IN AN ADULT IN COMBINATION WITH RILPIVIRINE

(3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5- ,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HIV-1 INFECTION IN ADULTS AND ADOLESCENTS 12 YEARS OF AGE AND OLDER AND WEIGHING AT LEAST 35 KG

(3S,11aR)-N-[2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5- ,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide useful as anti-HIV agent
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: TREATMENT OF HIV INFECTION IN ADULTS

FDA Regulatory Exclusivity protecting VOCABRIA

NEW CHEMICAL ENTITY
Exclusivity Expiration: See Plans and Pricing

REVISION TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY 207966 ATLAS-2M
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viiv Hlthcare VOCABRIA cabotegravir sodium TABLET;ORAL 212887-001 Jan 21, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Viiv Hlthcare VOCABRIA cabotegravir sodium TABLET;ORAL 212887-001 Jan 21, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Viiv Hlthcare VOCABRIA cabotegravir sodium TABLET;ORAL 212887-001 Jan 21, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Viiv Hlthcare VOCABRIA cabotegravir sodium TABLET;ORAL 212887-001 Jan 21, 2021 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for VOCABRIA

When does loss-of-exclusivity occur for VOCABRIA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 06239177
Estimated Expiration: See Plans and Pricing

Patent: 06307101
Estimated Expiration: See Plans and Pricing

Austria

Patent: 6026
Estimated Expiration: See Plans and Pricing

Brazil

Patent: 0610030
Estimated Expiration: See Plans and Pricing

Patent: 0617842
Estimated Expiration: See Plans and Pricing

Canada

Patent: 06282
Estimated Expiration: See Plans and Pricing

Patent: 26956
Estimated Expiration: See Plans and Pricing

China

Patent: 1212903
Estimated Expiration: See Plans and Pricing

Patent: 1346376
Estimated Expiration: See Plans and Pricing

Cyprus

Patent: 15151
Estimated Expiration: See Plans and Pricing

Patent: 16331
Estimated Expiration: See Plans and Pricing

Patent: 20345
Estimated Expiration: See Plans and Pricing

Denmark

Patent: 74117
Estimated Expiration: See Plans and Pricing

Patent: 65580
Estimated Expiration: See Plans and Pricing

Patent: 45206
Estimated Expiration: See Plans and Pricing

Patent: 87225
Estimated Expiration: See Plans and Pricing

Patent: 84520
Estimated Expiration: See Plans and Pricing

Patent: 72281
Estimated Expiration: See Plans and Pricing

Eurasian Patent Organization

Patent: 4162
Estimated Expiration: See Plans and Pricing

Patent: 0702080
Estimated Expiration: See Plans and Pricing

Patent: 0801144
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 52434
Estimated Expiration: See Plans and Pricing

Patent: 74117
Estimated Expiration: See Plans and Pricing

Patent: 50212
Estimated Expiration: See Plans and Pricing

Patent: 65580
Estimated Expiration: See Plans and Pricing

Patent: 27007
Estimated Expiration: See Plans and Pricing

Patent: 45206
Estimated Expiration: See Plans and Pricing

Patent: 87225
Estimated Expiration: See Plans and Pricing

Patent: 87226
Estimated Expiration: See Plans and Pricing

Patent: 84519
Estimated Expiration: See Plans and Pricing

Patent: 84520
Estimated Expiration: See Plans and Pricing

Patent: 72281
Estimated Expiration: See Plans and Pricing

Hong Kong

Patent: 07227
Estimated Expiration: See Plans and Pricing

Patent: 72282
Estimated Expiration: See Plans and Pricing

Patent: 49742
Estimated Expiration: See Plans and Pricing

Patent: 51191
Estimated Expiration: See Plans and Pricing

Hungary

Patent: 37795
Estimated Expiration: See Plans and Pricing

Patent: 44978
Estimated Expiration: See Plans and Pricing

Patent: 56603
Estimated Expiration: See Plans and Pricing

Patent: 400039
Estimated Expiration: See Plans and Pricing

Patent: 100022
Estimated Expiration: See Plans and Pricing

Patent: 100023
Estimated Expiration: See Plans and Pricing

Israel

Patent: 6555
Estimated Expiration: See Plans and Pricing

Patent: 0879
Estimated Expiration: See Plans and Pricing

Patent: 5788
Estimated Expiration: See Plans and Pricing

Patent: 5206
Estimated Expiration: See Plans and Pricing

Patent: 5207
Estimated Expiration: See Plans and Pricing

Japan

Patent: 2006088173
Estimated Expiration: See Plans and Pricing

Patent: 2007049675
Estimated Expiration: See Plans and Pricing

Patent: 95353
Estimated Expiration: See Plans and Pricing

Patent: 31689
Estimated Expiration: See Plans and Pricing

Patent: 17257
Estimated Expiration: See Plans and Pricing

Patent: 08540343
Estimated Expiration: See Plans and Pricing

Patent: 09079058
Estimated Expiration: See Plans and Pricing

Lithuania

Patent: 2021512
Estimated Expiration: See Plans and Pricing

Patent: 45206
Estimated Expiration: See Plans and Pricing

Patent: 84520
Estimated Expiration: See Plans and Pricing

Patent: 72281
Estimated Expiration: See Plans and Pricing

Luxembourg

Patent: 446
Estimated Expiration: See Plans and Pricing

Mexico

Patent: 2718
Estimated Expiration: See Plans and Pricing

Patent: 2216
Estimated Expiration: See Plans and Pricing

Patent: 07013351
Estimated Expiration: See Plans and Pricing

Patent: 08005137
Estimated Expiration: See Plans and Pricing

Morocco

Patent: 460
Estimated Expiration: See Plans and Pricing

Patent: 879
Estimated Expiration: See Plans and Pricing

Netherlands

Patent: 0676
Estimated Expiration: See Plans and Pricing

Patent: 1109
Estimated Expiration: See Plans and Pricing

New Zealand

Patent: 2339
Estimated Expiration: See Plans and Pricing

Norway

Patent: 9525
Estimated Expiration: See Plans and Pricing

Patent: 0111
Estimated Expiration: See Plans and Pricing

Patent: 17010
Estimated Expiration: See Plans and Pricing

Patent: 21018
Estimated Expiration: See Plans and Pricing

Patent: 075165
Estimated Expiration: See Plans and Pricing

Patent: 081892
Estimated Expiration: See Plans and Pricing

Patent: 161315
Estimated Expiration: See Plans and Pricing

Philippines

Patent: 007502373
Estimated Expiration: See Plans and Pricing

Poland

Patent: 74117
Estimated Expiration: See Plans and Pricing

Patent: 65580
Estimated Expiration: See Plans and Pricing

Patent: 45206
Estimated Expiration: See Plans and Pricing

Patent: 84520
Estimated Expiration: See Plans and Pricing

Patent: 72281
Estimated Expiration: See Plans and Pricing

Portugal

Patent: 74117
Estimated Expiration: See Plans and Pricing

Patent: 65580
Estimated Expiration: See Plans and Pricing

Patent: 45206
Estimated Expiration: See Plans and Pricing

Patent: 84520
Estimated Expiration: See Plans and Pricing

Patent: 72281
Estimated Expiration: See Plans and Pricing

Slovenia

Patent: 74117
Estimated Expiration: See Plans and Pricing

Patent: 65580
Estimated Expiration: See Plans and Pricing

Patent: 45206
Estimated Expiration: See Plans and Pricing

Patent: 87225
Estimated Expiration: See Plans and Pricing

Patent: 84520
Estimated Expiration: See Plans and Pricing

Patent: 72281
Estimated Expiration: See Plans and Pricing

South Africa

Patent: 0708970
Estimated Expiration: See Plans and Pricing

Patent: 0803423
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 1363875
Estimated Expiration: See Plans and Pricing

Patent: 1504998
Estimated Expiration: See Plans and Pricing

Patent: 1580310
Estimated Expiration: See Plans and Pricing

Patent: 1848819
Estimated Expiration: See Plans and Pricing

Patent: 080009733
Estimated Expiration: See Plans and Pricing

Patent: 080064182
Estimated Expiration: See Plans and Pricing

Patent: 130133061
Estimated Expiration: See Plans and Pricing

Patent: 140097438
Estimated Expiration: See Plans and Pricing

Patent: 160003889
Estimated Expiration: See Plans and Pricing

Spain

Patent: 37268
Estimated Expiration: See Plans and Pricing

Patent: 46324
Estimated Expiration: See Plans and Pricing

Patent: 67197
Estimated Expiration: See Plans and Pricing

Patent: 69357
Estimated Expiration: See Plans and Pricing

Patent: 67868
Estimated Expiration: See Plans and Pricing

Patent: 43531
Estimated Expiration: See Plans and Pricing

Patent: 92304
Estimated Expiration: See Plans and Pricing

Patent: 06792
Estimated Expiration: See Plans and Pricing

Taiwan

Patent: 78931
Estimated Expiration: See Plans and Pricing

Patent: 0716635
Estimated Expiration: See Plans and Pricing

Patent: 0800988
Estimated Expiration: See Plans and Pricing

Ukraine

Patent: 568
Estimated Expiration: See Plans and Pricing

Viet Nam

Patent: 404
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering VOCABRIA around the world.

Country Patent Number Title Estimated Expiration
Australia 2006239177 Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity See Plans and Pricing
Mexico 2007013351 DERIVADO DE CARBAMOILPIRIDONA POLICICLICO QUE TIENE ACTIVIDAD INHIBIDORA DE LA INTEGRASA DE HIV. (POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY.) See Plans and Pricing
South Korea 101363875 See Plans and Pricing
Spain 2906792 See Plans and Pricing
World Intellectual Property Organization (WIPO) 2006088173 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for VOCABRIA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1874117 CA 2014 00032 Denmark See Plans and Pricing PRODUCT NAME: DOLUTEGRAVIR ELLER ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF, HERUNDER DOLUTEGRAVIRNATRIUM; REG. NO/DATE: EU/1/13/892/001-002 20140116
2465580 2021C/519 Belgium See Plans and Pricing PRODUCT NAME: VOCABRIA-CABOTEGRAVIR; AUTHORISATION NUMBER AND DATE: EU/1/20/1481 20201221
1874117 C01874117/01 Switzerland See Plans and Pricing PRODUCT NAME: DOLUTEGRAVIR; REGISTRATION NO/DATE: SWISSMEDIC 63052 08.05.2014
1874117 C20140020 00130 Estonia See Plans and Pricing PRODUCT NAME: DOLUTEGRAVIIR;REG NO/DATE: K(2014)305 (LOPLIK) 21.01.2014
1874117 CR 2014 00032 Denmark See Plans and Pricing PRODUCT NAME: DOLUTEGRAVIR ELLER ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF, HERUNDER DOLUTEGRAVIRNATRIUM; REG. NO/DATE: EU/1/13/892/001-002 20140121
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Colorcon
Baxter
Dow
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.